<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02280278</url>
  </required_header>
  <id_info>
    <org_study_id>5010010</org_study_id>
    <nct_id>NCT02280278</nct_id>
  </id_info>
  <brief_title>Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy</brief_title>
  <official_title>The Effectiveness and Safety of Adjuvant Cytokine-induced Killer Cell Immunotherapy for Stage III Colorectal Cancer Patients After Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize through this randomized, prospective, single center adjuvant study, that
      cytokine-induced killer cell in patients with stage III colon cancer can improve survival in
      this patient population over control. Stage III colon cancer patients can benefit most from
      adjuvant chemotherapy, but the 5 year survival rate is still around 60%. We wish CIK cell
      therapy can improve the survival rate of stage III colon cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxin-side effect</measure>
    <time_frame>1 year</time_frame>
    <description>Toxin-side effect will be assessed by laboratory test, clinicians and questionary</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Stage III Colon Cancer</condition>
  <arm_group>
    <arm_group_label>CIK group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 8 cycles of CIK therapy in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stage III Colon Cancer patients will only receive radical operation and adjuvant chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical surgery</intervention_name>
    <arm_group_label>CIK group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant chemotherapy</intervention_name>
    <arm_group_label>CIK group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cytokine-induced killer cell immunotherapy</intervention_name>
    <arm_group_label>CIK group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatient of ≥ 18 years of age or ≥ country's legal age for adult
             consent

          -  Stage III colon cancer

          -  undergone complete resection of primary tumor

          -  Completed standard adjuvant chemotherapy

          -  within 120 days of completion of standard therapy

          -  ECOG performancer status 0-2

          -  Satisfactory haematological or biochemical functions (tests should be carried out
             within 8 weeks prior to randomisation): Results of clinical investigations carried out
             within 8 weeks prior to randomisation can be used in place of the required screening
             investigations. Patients with mild laboratory abnormalities can be included at the
             discretion by the site principal investigator, and after approval by ASCOLT Trial
             Management Group

          -  ANC ≥ 1.0 x 109/L

          -  Platelets ≥ 100 x 109/L

          -  Creatinine clearance ≥ 30 mL/min

          -  Total bilirubin ≤ 2.0 x the upper limit normal

          -  AST &amp; ALT ≤ 5 x the upper limit normal

          -  Completed the following investigations

          -  Completed the following investigations

        Exclusion Criteria:

          -  HIV positive or other Immunodeficiency disease

          -  recently use of high dose glucocorticoid

          -  Uncontrolled hypertension (untreated systolic blood pressure &gt; 160 mmHg, or diastolic
             blood pressure &gt; 95 mmHg)

          -  History of recent cancers (except for colorectal cancers, non-melanoma skin cancers,
             basal cell carcinomas, squamous cell carcinomas) in the past 5 years

          -  Patient having known allergy to capecitabine or Oxaliplatin

          -  Pregnant, lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-Jun Wu, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-Jun Wu, Prof.</last_name>
    <phone>+86 20 87343456</phone>
    <email>wuxj@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>De-Sen Wan, Prof.</last_name>
    <phone>+86 20 87343456</phone>
    <email>wands@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guagzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong-Xin Zhang, Doc.</last_name>
      <phone>+86 20 87343456</phone>
      <email>zhangrx@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xiao-Shi Zhang, Doc.</last_name>
      <phone>+86 20 87343456</phone>
      <email>zhangxs@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Xiao-Jun Wu, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rong-Xin Zhang, Doc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhi-Zhong Pan, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiao-Shi Zhang, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jian-Chuan Xia, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dan-Dan Li, Doc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gong Chen, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhen-Hai Lu, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Jing Fang, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li-Heng Kong, Doc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun-Zhong Lin, Doc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xiao-Jun Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>cytokine-induced killer cell immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

